SEC Form 4 · accession 0000899243-18-017965
Tectonic Therapeutic, Inc. · TECX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
SV Life Sciences Fund VI, L.P.
10% Owner
SVLSF VI, LLC
10% Owner
SV Life Sciences Fund VI (GP), L.P.
10% Owner
Period of report
Jun 25, 2018
Accepted (ET)
Jun 25, 2018 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 25, 2018 | C | 2,207,843 | — | A | 2,207,843 | I | See Footnote |
| Common StockF3,F4 | Jun 25, 2018 | C | 75,591 | — | A | 75,591 | I | See Footnote |
| Common StockF5,F2 | Jun 25, 2018 | C | 437,611 | — | A | 2,645,454 | I | See Footnote |
| Common StockF6,F4 | Jun 25, 2018 | C | 14,982 | — | A | 90,573 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF2,F3,F7 | — | Jun 25, 2018 | C | 9,122,809 | D | — | — | Common Stock | 2,207,843 | 0 | I |
| Series A Preferred StockF4,F3,F7 | — | Jun 25, 2018 | C | 312,341 | D | — | — | Common Stock | 75,591 | 0 | I |
| Series B Preferred StockF2,F3,F7 | — | Jun 25, 2018 | C | 1,808,211 | D | — | — | Common Stock | 437,611 | 0 | I |
| Series B Preferred StockF4,F3,F7 | — | Jun 25, 2018 | C | 61,908 | D | — | — | Common Stock | 14,982 | 0 | I |
Explanation of responses
- F1Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI, L.P. ("SV Life LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
- F2The shares are held directly by SV Life LP. SV Health Investors, LLC is the Manager of SV Life LP. SV Life Sciences Fund VI (GP), L.P., ("SV Fund VI GP") is the general partner of SV Life LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life LP, except to the extent of any pecuniary interest therein.
- F3Represents the total number of shares of Common Stock received by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Life SP LP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
- F4The shares are held directly by SV Life SP LP. SV Health Investors, LLC is the Manager of SV Life SP LP. SV Fund VI GP is the general partner of SV Life SP LP. The general partner of SV Fund VI GP is SVLSF VI, LLC. The members of the investment committee of SVLSF VI, LLC are Kate Bingham, Thomas Flynn, James Garvey, Eugene D. Hill, III, Paul LaViolette, and Michael Ross. Each of SV Fund VI GP, SVLSF VI, LLC and the SVLSF VI, LLC investment committee disclaims beneficial ownership of the shares owned directly by SV Life SP LP, except to the extent of any pecuniary interest therein.
- F5Represents the total number of shares of Common Stock received by SV Life LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
- F6Represents the total number of shares of Common Stock received by SV Life SP LP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
- F7All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.132-for-1 basis on June 25, 2018 and had no expiration date.